Table 1 Patient Characteristics and Comorbidities Before and After Matching (Demographics)
Before matching | After matching | |||||
|---|---|---|---|---|---|---|
Patients with relapse (n = 7122) | Patients without relapse (n = 12,792) | p value | Patients with relapse (n = 7093) | Patients without relapse (n = 7093) | p value | |
Characteristics | ||||||
Age, years | ||||||
Mean (SD) | 42.0 (13.4) | 42.4 (13.0) | .0482 | 42.0 (13.4) | 41.9 (13.3) | .7736 |
Age group, years, n (%) | ||||||
18 − 29 | 1601 (22.5) | 2586 (20.2) | .0053 | 1591 (22.4) | 1589 (22.4) | .9789 |
30 − 39 | 1223 (17.2) | 2336 (18.3) | 1222 (17.2) | 1226 (17.3) | ||
40 − 49 | 1796 (25.2) | 3313 (25.9) | 1791 (25.3) | 1811 (25.5) | ||
50 − 59 | 1871 (26.3) | 3444 (26.9) | 1867 (26.3) | 1873 (26.4) | ||
60 − 69 | 612 (8.6) | 1082 (8.5) | 606 (8.5) | 578 (8.1) | ||
70 − 79 | 15 (0.2) | 29 (0.2) | 15 (0.2) | 14 (0.2) | ||
≥ 80 | 4 (0.1) | 2 (0.0) | 1 (0.0) | 2 (0.0) | ||
Sex, n (%) | ||||||
Female | 4546 (63.8) | 7926 (62.0) | .0090 | 4524 (63.8) | 4539 (64.0) | .8067 |
Male | 2576 (36.2) | 4866 (38.0) | 2569 (36.2) | 2554 (36.0) | ||
Plan type, n (%)a | ||||||
PPO/POS | 4132 (58.0) | 7767 (60.7) | <.0001 | 4123 (58.1) | 4088 (57.6) | .6854 |
HMO | 883 (12.4) | 1728 (13.5) | 883 (12.4) | 916 (12.9) | ||
Other | 2107 (29.6) | 3297 (25.8) | 2087 (29.4) | 2089 (29.5) | ||
Comorbidities | ||||||
Substance/alcohol abuse disorder | 1409 (19.8) | 1677 (13.1) | <.0001 | 1383 (19.5) | 1399 (19.7) | .7511 |
Type 2 diabetes mellitus | 740 (10.4) | 1224 (9.6) | .0630 | 731 (10.3) | 675 (9.5) | .1222 |
Obesity | 1047 (14.7) | 1886 (14.7) | .9501 | 1043 (14.7) | 971 (13.7) | .0876 |
Hyperlipidemia | 2282 (32.0) | 4190 (32.8) | .3050 | 2267 (32.0) | 2175 (30.7) | .0995 |
Hypertension | 2021 (28.4) | 3497 (27.3) | .1167 | 2003 (28.2) | 1857 (26.2) | .0062 |
Chronic kidney disease | 100 (1.4) | 164 (1.3) | .4775 | 97 (1.4) | 90 (1.3) | .6588 |
Coronary heart disease | 297 (4.2) | 540 (4.2) | .8829 | 292 (4.1) | 248 (3.5) | .0591 |
Congestive heart failure | 202 (2.8) | 396 (3.1) | .3192 | 201 (2.8) | 161 (2.3) | .0377 |
Cerebrovascular disease | 317 (4.5) | 434 (3.4) | .0002 | 304 (4.3) | 285 (4.0) | .4487 |
Peripheral vascular disease | 245 (3.4) | 382 (3.0) | .0826 | 240 (3.4) | 230 (3.2) | .6729 |
Cancer | 2296 (32.2) | 4082 (31.9) | .6346 | 2280 (32.1) | 2254 (31.8) | .6526 |
Anxiety disorder | 3749 (52.6) | 6111 (47.8) | <.0001 | 3722 (52.5) | 3653 (51.5) | .2531 |
Sleeping disorder | 1374 (19.3) | 2222 (17.4) | .0008 | 1360 (19.2) | 1313 (18.5) | .3233 |
COPD | 291 (4.1) | 368 (2.9) | <.0001 | 277 (3.9) | 265 (3.7) | .6300 |
Parkinson disease | 15 (0.2) | 19 (0.1) | .3705 | 14 (0.2) | 14 (0.2) | >.99 |
Multiple sclerosis | 43 (0.6) | 79 (0.6) | >.99 | 43 (0.6) | 39 (0.5) | .7399 |
Gastrointestinal disorder | 1590 (22.3) | 2582 (20.2) | .0004 | 1573 (22.2) | 1591 (22.4) | .7317 |